Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin in Visceral Adiposity
2005-001048-22Phase 2
Key facts
- Status
- Completed
- Start
- Aug 2005
- Countries
- 1
- Sponsor
- University of Gothenburg
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Drugs
- rosuvastatin
- Conditions
- Abdominal adiposity (ABCD)dyslipidemia
01
Overview
Phase 2, randomised, double-blind trial in Abdominal adiposity (ABCD) and dyslipidemia comparing Rosuvastatin with Placebo (2 arms). Primary endpoint: Change in intra-abdominal adipose tissue area. Started Aug 2005; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Rosuvastatin
Participants received rosuvastatin in a double-blind parallel-group design.
Placebo
Participants received placebo in a double-blind parallel-group design.
03
Who it enrols
Adult men aged 40 to 65 years with abdominal obesity defined by waist circumference at least 102 cm and dyslipidemia were eligible. Patients with uncontrolled hypertension, diabetes mellitus, severe liver disease, severe renal impairment, endocrine disorders, malignant disease, myopathic disease, substance abuse, or ongoing treatment with statins, anti-obesity drugs, anti-inflammatory drugs, or immunosuppressive drugs were excluded.
04
Endpoints
Primary
Change in intra-abdominal adipose tissue area
Secondary
Fatty infiltration in the liver
Muscle attenuation values
Glycemia
Lipid levels
Gene expression in subcutaneous adipose tissue
Beyond the preview
Go deeper on 2005-001048-22.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001048-22.